| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
19α-Hydroxyasiatic acid targets the extrinsic coagulation pathway, exhibiting significant anticoagulant activity. It also exhibits anti-elastase activity and inhibits LPS-induced NF-kappaB activation in HEK293 cells. These activities suggest potential applications in thrombosis, inflammation, and tissue remodeling.
|
|---|---|
| ln Vitro |
In vitro, 19α-Hydroxyasiatic acid demonstrates anti-elastase activity and inhibits LPS-induced NF-kappaB activation in HEK293 cells. It also exhibits significant anticoagulant effect on the extrinsic pathway. These activities indicate potential anti-inflammatory and anticoagulant properties.
|
| ln Vivo |
In vivo, 19α-Hydroxyasiatic acid's anticoagulant effect on the extrinsic pathway suggests potential therapeutic applications in thrombotic disorders. However, detailed in vivo efficacy data in animal models are limited and require further investigation. The compound's anti-inflammatory properties also warrant in vivo evaluation.
|
| Enzyme Assay |
Cell-free assays for 19α-Hydroxyasiatic acid include anticoagulant activity assays measuring the compound's effect on the extrinsic pathway using prothrombin time (PT) or other coagulation tests. Anti-elastase activity is assessed using elastase inhibition assays with chromogenic substrates. NF-kappaB inhibition is evaluated using reporter gene assays in cell lysates.
|
| Cell Assay |
In vitro cellular assays involve treating HEK293 cells with 19α-Hydroxyasiatic acid and measuring LPS-induced NF-kappaB activation using luciferase reporter assays. Anti-elastase activity can be assessed in cell-based systems using elastase-secreting cells. Anticoagulant effects are evaluated using plasma-based clotting assays.
|
| Animal Protocol |
In vivo animal studies for 19α-Hydroxyasiatic acid would typically involve administration in rodent models of thrombosis or inflammation. Endpoints include measurements of clotting parameters, inflammatory markers, and histopathological examination of affected tissues. The compound's anticoagulant and anti-inflammatory activities support further investigation in these areas.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 19α-Hydroxyasiatic acid have not been extensively reported. As a pentacyclic triterpenoid, it is expected to have moderate lipophilicity and potential for oral absorption. The compound's metabolism, distribution, and elimination pathways require further characterization through dedicated PK studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for 19α-Hydroxyasiatic acid are limited. As a naturally occurring triterpenoid, it is generally considered to have a manageable safety profile at research doses. Standard toxicity assessments including acute, sub-chronic, and genotoxicity studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
19α-Hydroxyasiatic acid is a pentacyclic triterpenoid compound formed by the substitution of a hydroxyl group at the 19-position of asiatic acid. It has been isolated from the leaves of Rosa laevigata. It possesses anti-inflammatory activity and is also a plant metabolite. It is a pentacyclic triterpenoid compound, a hydroxy monocarboxylic acid, and a tetraol. Its function is related to asiatic acid. It is derived from the hydride of arbutin. 19α-Hydroxyasiatic acid has been reported to exist in Rosa laevigata, Rubus pungens, and other organisms with relevant data.
19α-Hydroxyasiatic acid is a research compound with no clinical approvals. Its pharmacological activities include anticoagulant effects on the extrinsic pathway, anti-elastase activity, and inhibition of LPS-induced NF-kappaB activation. The compound is a valuable tool for studying coagulation, inflammation, and tissue remodeling. Its natural occurrence in medicinal plants supports further investigation. |
| Molecular Formula |
C30H48O6
|
|---|---|
| Molecular Weight |
504.70
|
| Exact Mass |
504.345
|
| CAS # |
70868-78-9
|
| PubChem CID |
490367
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
283℃
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
36
|
| Complexity |
979
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@H]([C@@H]([C@@]5(C)CO)O)O)C)C)[C@@H]2[C@]1(C)O)C)C(=O)O
|
| InChi Key |
YCOKATFNRPZIIU-NIZSJLHKSA-N
|
| InChi Code |
InChI=1S/C30H48O6/c1-17-9-12-30(24(34)35)14-13-27(4)18(22(30)29(17,6)36)7-8-21-25(2)15-19(32)23(33)26(3,16-31)20(25)10-11-28(21,27)5/h7,17,19-23,31-33,36H,8-16H2,1-6H3,(H,34,35)/t17-,19-,20-,21-,22-,23+,25+,26+,27-,28-,29-,30+/m1/s1
|
| Chemical Name |
(1R,2R,4aS,6aR,6aS,6bR,8aR,9R,10R,11R,12aR,14bS)-1,10,11-trihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9814 mL | 9.9069 mL | 19.8138 mL | |
| 5 mM | 0.3963 mL | 1.9814 mL | 3.9628 mL | |
| 10 mM | 0.1981 mL | 0.9907 mL | 1.9814 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
